Anifrolumab

Status:: Do Not Prescribe (DNP)
Decision Date:: February 2022

Comments

DNP:

NICE TA793 - Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal). (Decision date - July 2022).